COMPOSITIONS FOR TREATMENT OF SUBSTANCE USE DISORDER

20220233479

17/628138

July 17, 2020

Certain embodiments are directed to methods of treating or preventing an addictive behavior in a subject, said method comprising administering to said subject an effective amount of a DMTU or a composition comprising same.

UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (Fort Worth, TX, US)

1. A method of treating or preventing an addictive behavior in a subject, the method comprising administering to said subject a composition comprising an effective amount of N,N′ dimethylthiourea (DMTU).

2. The method according to claim 1, wherein the addictive behavior is exhibited by the subject following exposure of the subject to at least one stimulus, the stimulus inducing the addictive behavior.

3. The method of claim 2, where in the stimulus is alcohol, caffeine, nicotine, cannabis, morphine, heroin, codeine, cocaine, hydrocodone, hydromorphone, levorphanol, metapon, nalorphine, naloxone, naltrexone, oxycodone, oxymorphone, tramadol, ethoheptazine, fentanyl, levorphanol, meperidine, methadone, phenazocine, propoxyphene, sufentanil, phencyclidine, benzodiazepines, methaqualone, mecloqualone, etaqualone, pemoline, amphetamine, methamphetamine, methylenedioxymethamphetamine, dextroamphetamine and methylamphetamine.

4. The method of claim 1, wherein DMTU is administered at 1 to 100 mg/kg.

5. The method of claim 1, wherein the DMTU is administered orally, intratracheally, intravenously, intramuscularly, intraperitoneally, percutaneously, topically, or subcutaneously.

6. The method of claim 1, wherein a subject is administered DMTU on a regular schedule.

7. The method of claim 1, wherein the subject is administered DMTU daily.

8. A method for mitigating relapse into addiction of a subject, the method comprising administering to said subject a composition comprising an effective amount of N,N′ dimethylthiourea (DMTU).

9. The method of claim 8, wherein DMTU is administered at 1 to 100 mg/kg.

10. The method of claim 8, wherein the DMTU is administered orally, intratracheally, intravenously, intramuscularly, intraperitoneally, percutaneously, topically, or subcutaneously.

11. The method of claim 8, wherein a subject is administered DMTU on a regular schedule.

12. The method of claim 8, wherein the subject is administered DMTU daily.

13. A method for reducing the addictive effect of re-exposure or continuous exposure to at least one agent, behavior, or stimulus which induces addictive behavior in a subject, wherein the subject is an addict or having a risk of developing addiction, the method comprising administering to said subject a composition comprising an effective amount of N,N′ dimethylthiourea (DMTU).

14. The method of claim 13, wherein DMTU is administered at 1 to 100 mg/kg.

15. The method of claim 13, wherein the DMTU is administered orally, intratracheally, intravenously, intramuscularly, intraperitoneally, percutaneously, topically, or subcutaneously.

16. The method of claim 13, wherein a subject is administered DMTU on a regular schedule.

17. The method of claim 13, wherein the subject is administered DMTU daily.

18. A method of treating or preventing or suppressing relapse to addiction, relapse use of an addictive agent or practice of an addictive or compulsive behavior in a subject, the method comprising administering to said subject a composition comprising an effective amount of N,N′ dimethylthiourea (DMTU).

19. The method of claim 18, wherein DMTU is administered at 1 to 100 mg/kg.

20. The method of claim 18, wherein the DMTU is administered orally, intratracheally, intravenously, intramuscularly, intraperitoneally, percutaneously, topically, or subcutaneously.

21. The method of claim 18, wherein a subject is administered DMTU on a regular schedule.

22. The method of claim 18, wherein the subject is administered DMTU daily.

23. A method of preventing an addiction in a subject, the method comprising identifying a subject having a predisposition to addiction or who is at risk of developing an addiction and administering to the subject an effective amount of N,N′ dimethylthiourea (DMTU).

24. The method according to claim 23, wherein the addiction is a physical dependence to an addictive agent or to an addictive behavior.

25. The method according to claim 24, wherein the addictive agent is selected from the group consisting of addictive recreational drugs and addictive medications.

26. The method according to claim 24, wherein said addictive agent is selected from the group consisting of alcohol, caffeine, nicotine, cannabis and cannabis derivatives, opiates and morphine-like compounds, phencyclidine and phencyclidine-like compounds, sedative hypnotics, psychostimulants, amphetamines and amphetamine-related drugs.

27. The method according to claim 24, wherein said addictive agent is selected from the group consisting of alcohol, caffeine, nicotine, cannabis, morphine, heroin, codeine, cocaine, hydrocodone, hydromorphone, levorphanol, metapon, nalorphine, naloxone, naltrexone, oxycodone, oxymorphone, tramadol, ethoheptazine, fentanyl, levorphanol, meperidine, methadone, phenazocine, propoxyphene, sufentanil, phencyclidine, benzodiazepines, methaqualone, mecloqualone, etaqualone, pemoline, amphetamine, methamphetamine, methylenedioxymethamphetamine, dextroamphetamine and methylamphetamine.

28. The method according to claim 27, wherein the addictive agent is cocaine.

29. The method according to claim 27, wherein the addictive agent is nicotine.

30. The method according to claim 24, wherein said addictive agent is a pain-killer or a combination of pain-killers.

31. The method according to claim 30, wherein the pain-killer is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacylmorphan, lofenitanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papavereturn, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propiram, propoxyphene sufentanil, tramadol and tilidine.

32. The method according to claim 24, wherein the addictive agent is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, apomorphine, benzylmorphine, beta-hydroxy 3-methylfentanyl, bezitramide, carfentanil, clonitazene, codeine, desomorphine, dextromoramide, diampromide, dihydrocodeine, dihydroetorphine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetylbutyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, fentanyl, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, metapon, metazocine, methadone, methadyl acetate, metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol, normethadone, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaverine, phenadoxone, phenomorphan, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propoxyphene, remifentanil, sufentanil, thebaine, tildine and tramadol.

33. The method according to claim 24, wherein said addictive behavior is selected from the group consisting of obsessive compulsive disorder, compulsive spending and/or gambling, pathological overeating, pathological use of electronic devices and communication devices such as cellular phones, pathological use of electronic video games, addiction to pornography and sex, eating disorders such as anorexia and bulimia, kleptomania, pyromania, compulsive over-exercising and overworking.

34. The method according to claim 24, wherein the addiction is to more than one of an addictive agent and/or addictive behavior.

35. The method of claim 24, wherein DMTU is administered at 1 to 100 mg/kg.

36. The method of claim 24, wherein the DMTU is administered orally, intratracheally, intravenously, intramuscularly, intraperitoneally, percutaneously, topically, or subcutaneously.

37. The method of claim 24, wherein a subject is administered DMTU on a regular schedule.

38. The method of claim 24, wherein the subject is administered DMTU daily.

39. A method for affecting memory retrieval in a subject prone to relapse into addiction or for diminishing, suppressing or minimizing addictive behavior, the method comprising administering to said subject an effective amount of N,N′dimethylthiourea (DMTU). prior, during or after intentional or unintentional exposure to a stimulus.

40. The method of claim 39, wherein DMTU is administered at 1 to 100 mg/kg.

41. The method of claim 39, wherein the DMTU is administered orally, intratracheally, intravenously, intramuscularly, intraperitoneally, percutaneously, topically, or subcutaneously.

42. The method of claim 39, wherein a subject is administered DMTU on a regular schedule.

43. The method of claim 39, wherein the subject is administered DMTU daily.

61; 61

edspap.20220233479